Navigation Links
Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
Date:8/23/2011

BELGRADE, Mont., Aug. 23, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has been invited to present at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held at The Waldorf Astoria Hotel in New York City on September 11-13, 2011.

Bacterin's chairman and CEO, Guy Cook, and CFO, John Gandolfo, are scheduled to present on Monday, September 12, 2011 at 1:35 p.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company's business plan and objectives for the remainder of 2011.

The presentation will be available via webcast at www.wsw.com/webcast/rrshq20/bone. A replay link will also be available for 90 days following the live presentation on the company's website at www.bacterin.com.

Bacterin recently reported record revenue for the second quarter 2011 of $7.5 million, up 25% sequentially and 135% year-over-year. The company also reported its first positive EBITDA quarter of $33,000.

For more information about the conference or to schedule a one-on-one meeting with Bacterin management, contact your Rodman & Renshaw representative or the conference desk at 212-920-3595.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com


'/>"/>
SOURCE Bacterin International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter
2. Bacterin Secures $15 Million Credit Facility with MidCap Financial and Silicon Valley Bank
3. Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET
4. Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes
5. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
6. Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results
7. Bacterin International Holdings Launches Third Biologic Scaffold
8. Bacterin International Holdings, Inc. Schedules Conference Call to Present Fourth Quarter and Full Year 2010 Financial Results
9. Bacterin International Holdings, Inc. Receives Approval for Listing on NYSE Amex
10. Bacterin International Announces Major Orthopedic Hospital Group to Begin Use of OsteoSponge®SC
11. Bacterin International to Announce Launch of OsteoSponge®SC at American Academy of Orthopedic Surgeons 2011 Annual Meeting February 15-19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... YORK , Feb. 23, 2017  Genesis Healthcare ... Company. The announcement was made by Bill Monast ... David Hartley and Nathan Feltman , executives ... Genesis Healthcare Services, LLC. This acquisition ... largest provider of technology enabled durable medical equipment (DME) ...
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... , Feb. 23, 2017 Research and Markets ... and Strategies - 2016" report to their offering. ... The latest research Fibromyalgia ... and benchmarks in the global Fibromyalgia market. The research ... key drugs marketed for Fibromyalgia and their clinical attributes? How are ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... On April 13, 2017, The ... “Doping in Sport: How the Culture Might Change,” in conjunction with Pepperdine ... will be held at Pepperdine University in Malibu, California. , Sir Philip Craven, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, ... trials, today announced that Premier Research, a leading clinical development service provider, has ... are becoming increasingly complex, due in part to an array of circumstances including ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center ... Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present ... spectrum disorder (ASD) to see films in an environment that accommodates their unique ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered from ... regime, the author was able to successfully recover. In “ Origin & Insertion Charts ... various sources on the principals of massage, anatomy , trigger points and ...
Breaking Medicine News(10 mins):